Indications

Daconib 45mg is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC), especially in patients with adenocarcinoma histology who have shown progression after first-line chemotherapy. It is also used in some cases of idiopathic pulmonary fibrosis (IPF) to slow disease progression. This medication offers targeted treatment for patients with specific tumor markers, providing hope for those with limited options.

Pharmacology

Daconib contains Nintedanib, a potent oral tyrosine kinase inhibitor that blocks multiple receptors involved in angiogenesis—the process by which tumors develop new blood vessels to sustain their growth. By inhibiting vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR), Daconib starves the tumor of its blood supply, leading to decreased tumor growth and proliferation. This multi-targeted approach makes Daconib a valuable agent in the fight against resistant and aggressive cancer types.

Dosage & Administration

The usual recommended dose of Daconib 45mg is twice daily (BID), taken orally with food to enhance absorption and reduce gastrointestinal discomfort. Patients should swallow the capsules whole with water. Dose adjustments may be necessary based on individual tolerance, liver function tests, and the occurrence of side effects. Regular clinical monitoring and laboratory tests are important to ensure safe and effective use.

Interaction

Daconib is metabolized mainly by the liver enzyme CYP3A4. Co-administration with strong CYP3A4 inhibitors (such as ketoconazole or ritonavir) can increase plasma levels of Daconib, raising the risk of toxicity. Conversely, CYP3A4 inducers (such as rifampin or phenytoin) may reduce its effectiveness. Patients should inform their healthcare provider of all medications, supplements, or herbal products to avoid harmful interactions.

Contraindications

Daconib is contraindicated in individuals with known hypersensitivity to Nintedanib or any component of the formulation. It should not be used in patients with severe hepatic impairment (Child-Pugh C) or those experiencing active bleeding disorders due to an increased risk of hemorrhagic events.

Side Effects

Common side effects reported with Daconib include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Liver enzyme elevations are also observed and warrant monitoring. Less frequent but serious adverse effects include bleeding, hypertension, arterial thromboembolic events, and gastrointestinal perforations. Prompt reporting of symptoms like unusual bleeding, severe abdominal pain, or persistent hypertension is critical.

Pregnancy & Lactation

Daconib carries potential risks to fetal development and is therefore contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose. It is unknown whether Daconib is excreted in human breast milk; hence, breastfeeding is not recommended during treatment and for an appropriate period afterward to avoid exposing the infant to potential harm.

Precautions & Warnings

Regular monitoring of liver function tests, blood pressure, and signs of bleeding is essential during Daconib therapy. Patients with a history of cardiovascular disease or bleeding disorders require careful assessment before initiation. Dose reductions or treatment interruptions may be needed if severe adverse reactions occur. Patients should be advised to avoid activities with a high risk of injury due to bleeding potential.

Overdose Effects

In the event of an overdose, patients may experience intensified side effects such as severe gastrointestinal distress, liver toxicity, or bleeding complications. Supportive care, including hydration and symptomatic treatment, should be provided. There is no specific antidote for Daconib overdose.

Therapeutic Class

Daconib belongs to the therapeutic class of Tyrosine Kinase Inhibitors (TKIs), which are targeted cancer therapies designed to interfere with specific molecular pathways critical for tumor growth and metastasis.

Storage Conditions

Store Daconib 45mg capsules in their original packaging, protected from moisture and light, at temperatures below 30°C. Ensure the medication is kept out of reach and sight of children to maintain safety.